RadChem 2018

Session

RPH 1

RPH.1

15 May 2018, 15:30

Casino Conference Centre

Conveners

RPH 1

• Ondřej Lebeda (Nuclear Physics Institute, Academy of Sciences of the Czech Republic)
• Constantin Mamat (HZDR)

470. Albumin-binding PSMA Ligands: Next Step Towards Improved Radionuclide Therapy of Prostate Cancer

Dr Martina Benesova (Paul Scherrer Institut, Center for Radiopharmaceutical Sciences ETH-PSI-USZ)

15/05/2018, 15:30

Radiopharmaceutical Chemistry, Labelled Compounds

Verbal

The prostate-specific membrane antigen (PSMA) has emerged as an attractive target for imaging and therapy of prostate cancer. Despite many advances in the past years, the treatment of metastatic castration-resistant prostate cancer (mCRPC) still remains challenging. The aim of this study was to optimize radionuclide therapy of mCRPC through the development of albumin-binding PSMA ligands with...

545. Sulfonated calix-baskets for complexation of Barium and Radium

Dr Constantin Mamat

15/05/2018, 15:45

Radiopharmaceutical Chemistry, Labelled Compounds

Verbal

Understanding the coordination chemistry of the heavy group 2 metal chemistry, especially of barium as surrogate for radium, is mandatory not only for adiopharmaceutical applications of radium. This is from high importance since Radium-223 is the only approved therapeutic alpha-emitter (by EMA and FDA). Unfortunately, the applications are limited. To date, radium-223 is only in use as...

605. Synthesis and radiofluorination of a novel monocarboxylate transporter 1 inhibitor for tumor imaging by PET

Dr Masoud Sadeghzadeh (Department of Neuroradiopharmaceuticals, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Research site Leipzig)

15/05/2018, 16:00

Radiopharmaceutical Chemistry, Labelled Compounds

Verbal

Monocarboxylate transporter 1 (MCT1) is an integral plasma membrane protein that bi-directionally transports lactate and ketone bodies and is highly expressed in non-hypoxic regions of human colon, brain, breast, lung and other tumors. Accordingly, MCT1 inhibitors are regarded to be of potential clinical use. In the current study we developed a new 18F-labeled radioligand for in vivo imaging...

560. Alpha Radionuclide Therapy Using Polymeric Nanocarriers

Dr Robin de Kruijff (Radiation Science and Technology, Delft University of Technology, Delft, the Netherlands)

15/05/2018, 16:15

Radiopharmaceutical Chemistry, Labelled Compounds

Verbal

Alpha radionuclide therapy (ART) is a very powerful tool for the treatment of small tumour metastases. Due to their short range and high LET, alpha particles are much more efficient at killing cells than the commonly used beta radiation. Furthermore, their short range stops them from destroying neighbouring healthy cells. One of the main problems which still needs to be solved before ART can...

685. 134Ce/134La for Positron Emission Tomography of Targeted Alpha Therapeutics

Veronika Mocko (Los Alamos National Laboratory)

15/05/2018, 16:30

Radiopharmaceutical Chemistry, Labelled Compounds

Verbal

The radionuclides employed in targeted alpha therapy are often actinides (e.g. 225Ac, 227Th) with multiple radioactive daughters. Successful treatment relies on the radiopharmaceutical’s ability to “hold-on” to 225Ac (or 227Th) while it is delivered to the target cancer cell. Imaging surrogates of the radiopharmaceutical permit non-invasive pharmacokinetic assays and enable rapid screening of...

593. 119Sb: promising radionuclide for Targeted Auger Therapy - Production radiochemical separation and chelation aspects.

Dr Valery Radchenko (Life Sciences Division, TRIUMF)

15/05/2018, 16:45

Radiopharmaceutical Chemistry, Labelled Compounds

Verbal

Introduction: 119Sb is one of the most potent radionuclides for Targeted Auger Therapy due to convenient energy and numbers of Auger electrons as well absence of any other accompanying emissions [1-3]. Antimony-119 has a half-life of 38.5 hours which is well suited for radiotherapeutic application. In the present work: production, radiochemical separation and chelation preference of...